1. In Vivo

Partnerships Picks For GeNeuro’s MS Antibody

GeNeuro’s CEO And His Mission To Bring Anti-HERV Benefits To MS Patients

 
• By Jo Shorthouse

The Geneva-based biotech has been developing its antibody temelimab for the last 16 years. Data from its Phase II studies show its need for a big pharma development partner.

teamwork
• Source: Shutterstock

Jesús Martin-Garcia, founder and CEO of Geneva-based GeNeuro SA, is a man on a mission. He has been forging a clinical path for what would become the monoclonal antibody temelimab (previously known as GNbAC1) to address disease progression in multiple sclerosis (MS) since 2006.

The last 16 years have been peppered with clinical development pivots, and the recent results of Phase II trials have...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Science

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.